BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 737K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

34 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
New bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones.EBI
Kyowa Hakko Kogyo
Synthesis and antiulcer activity of 5,11-dihydro[1]benzoxepino[3,4-b]pyridines.EBI
Kyowa Hakko Kogyo
Novel 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran derivatives as selective alpha(2C)-adrenergic receptor antagonists.EBI
Kyowa Hakko Kogyo
Potent and selective inhibitors of PDGF receptor phosphorylation. 2. Synthesis, structure activity relationship, improvement of aqueous solubility, and biological effects of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.EBI
Kyowa Hakko Kogyo
Indole derivatives as a new class of steroid 5 alpha-reductase inhibitors.EBI
Kyowa Hakko Kogyo
5-HT3 receptor antagonists. 2. 4-Hydroxy-3-quinolinecarboxylic acid derivatives.EBI
Kyowa Hakko Kogyo
Synthesis of 2-imidazolidinylidenepropanedinitrile derivatives as stimulators of gastrointestinal motility.EBI
Kyowa Hakko Kogyo
Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine.EBI
Kyowa Hakko Kogyo
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.EBI
Kyowa Hakko Kogyo
8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.EBI
Kyowa Hakko Kogyo
5-HT3 receptor antagonists. 1. New quinoline derivatives.EBI
Kyowa Hakko Kogyo
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.EBI
Kyowa Hakko Kogyo
Synthesis and antiallergic activity of 11-(aminoalkylidene)-6,11-dihydrodibenz[b,e]oxepin derivatives.EBI
Kyowa Hakko Kogyo
Inhibition of eEF2-K by thieno[2,3-b]pyridine analogues.EBI
Kyowa Hakko Kogyo
2-Anilino-4-aryl-1,3-thiazole inhibitors of valosin-containing protein (VCP or p97).EBI
Kyowa Hakko Kogyo
Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors.EBI
Kyowa Hakko Kogyo
Diamine derivatives containing imidazolidinylidene propanedinitrile as a new class of histamine H3 receptor antagonists. Part I.EBI
Kyowa Hakko Kogyo
Synthetic study of VLA-4/VCAM-1 inhibitors: synthesis and structure-activity relationship of piperazinylphenylalanine derivatives.EBI
Kyowa Hakko Kogyo
Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. Part 4: structure-activity relationships for substituents on the quinazoline moiety of 4-[4-(N-substituted(thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.EBI
Kyowa Hakko Kogyo
Improvement of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide.EBI
Kyowa Hakko Kogyo
Mixed lineage kinase activity of indolocarbazole analogues.EBI
Kyowa Hakko Kogyo
Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives.EBI
Kyowa Hakko Kogyo
Dibenzoxepin derivatives: thromboxane A2 synthase inhibition and thromboxane A2 receptor antagonism combined in one molecule.EBI
Kyowa Hakko Kogyo
Inhibitors of acyl-CoA:cholesterol acyltransferase. 1. Synthesis and hypocholesterolemic activity of dibenz[b,e]oxepin-11-carboxanilides.EBI
Kyowa Hakko Kogyo
Dibenz[b,e]oxepin derivatives: novel antiallergic agents possessing thromboxane A2 and histamine H1 dual antagonizing activity. 1.EBI
Kyowa Hakko Kogyo
Novel 5-aminoflavone derivatives as specific antitumor agents in breast cancer.EBI
Kyowa Hakko Kogyo
(E)-4-(2-[[3-(indol-5-yl)-1-oxo-2-butenyl]amino]phenoxy)butyric acid derivatives: a new class of steroid 5 alpha-reductase inhibitors in the rat prostate. 1.EBI
Kyowa Hakko Kogyo
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.EBI
Kyowa Hakko Kogyo
(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.EBI
Kyowa Hakko Kogyo
7,8-Dihydro-8-ethyl-2-(3-noradamantyl)-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one: a potent and water-soluble adenosine A1 antagonist.EBI
Kyowa Hakko Kogyo
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 2.EBI
Kyowa Hakko Kogyo
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.EBI
Kyowa Hakko Kogyo
Inhibition of MCL-1 and/or BFL-1/A1BDB
Dana-Farber Cancer Institute